MX2018001314A - Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica. - Google Patents

Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.

Info

Publication number
MX2018001314A
MX2018001314A MX2018001314A MX2018001314A MX2018001314A MX 2018001314 A MX2018001314 A MX 2018001314A MX 2018001314 A MX2018001314 A MX 2018001314A MX 2018001314 A MX2018001314 A MX 2018001314A MX 2018001314 A MX2018001314 A MX 2018001314A
Authority
MX
Mexico
Prior art keywords
natriuretic peptide
type natriuretic
skeletal dysplasia
peptide variants
cnp
Prior art date
Application number
MX2018001314A
Other languages
English (en)
Inventor
O Okhamafe Augustus
Bullens Sherry
Bunting Stuart
Chou Tianwei
P Price Christopher
J Went Daniel
YAP Clarence
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2018001314A publication Critical patent/MX2018001314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

La presente descripción se refiere al uso de variantes del péptido natriurético de tipo C (CNP), así como a formulaciones y composiciones farmacéuticas novedosas que comprenden las variantes de los péptidos CNP para el tratamiento de displasias esqueléticas, uno o más síntomas de las displasias esqueléticas, tales como crecimiento de hueso largo o velocidad de crecimiento, y otros trastornos que tienen una displasia esquelética y/o un componente o síntoma asociado con un CNP.
MX2018001314A 2015-07-30 2016-08-01 Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica. MX2018001314A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199081P 2015-07-30 2015-07-30
US201662320704P 2016-04-11 2016-04-11
PCT/US2016/044968 WO2017020034A1 (en) 2015-07-30 2016-08-01 Use of c-type natriuretic peptide variants to treat skeletal dysplasia

Publications (1)

Publication Number Publication Date
MX2018001314A true MX2018001314A (es) 2018-05-28

Family

ID=56682280

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001314A MX2018001314A (es) 2015-07-30 2016-08-01 Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
MX2023002973A MX2023002973A (es) 2015-07-30 2018-01-30 Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002973A MX2023002973A (es) 2015-07-30 2018-01-30 Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.

Country Status (18)

Country Link
US (5) US9907834B2 (es)
EP (1) EP3328416B1 (es)
JP (3) JP6882256B2 (es)
KR (1) KR20180030414A (es)
CN (2) CN108472336B (es)
AU (2) AU2016298425B2 (es)
BR (1) BR112018001761A2 (es)
CA (1) CA2994280C (es)
CL (1) CL2018000215A1 (es)
CO (1) CO2018002328A2 (es)
DK (1) DK3328416T3 (es)
FI (1) FI3328416T3 (es)
HK (1) HK1255864A1 (es)
IL (2) IL257125B (es)
MX (2) MX2018001314A (es)
RU (1) RU2728567C2 (es)
TW (2) TWI820795B (es)
WO (1) WO2017020034A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180030414A (ko) 2015-07-30 2018-03-22 바이오마린 파머수티컬 인크. 골 이형성증 치료를 위한 c―형 나트륨이뇨 펩타이드 변이체의 용도
US20200030414A1 (en) * 2017-01-24 2020-01-30 Daiichi Sankyo Company, Limited Therapeutic agent for short stature
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
JP7197310B2 (ja) * 2018-08-31 2022-12-27 株式会社小松製作所 積込機械の制御装置および制御方法
US20220280647A1 (en) * 2019-08-12 2022-09-08 Biomarin Pharmaceutical Inc. Hydrophobic Peptide Salts for Extended Release Compositions
CN110514619B (zh) * 2019-08-29 2021-01-29 山东科技大学 基于有偏估计的近红外定量分析模型构建方法
MX2022003184A (es) * 2019-09-16 2022-06-23 Biomarin Pharm Inc Variantes del cnp y sus conjugados.
WO2023283657A1 (en) 2021-07-09 2023-01-12 Biomarin Pharmaceutical Inc. C-type natriuretic peptide variants to treat skeletal dysplasia in children
WO2023108005A1 (en) 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0478797T3 (da) 1990-04-20 1995-06-26 Hisayuki Matsuo Nyt fysiologisk aktivt peptid stammende fra gris
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2009086166A1 (en) * 2007-12-19 2009-07-09 Ekr Therapeutics, Inc. Room temperature stable, lyophilized natriuretic peptide formulations
MX2011012277A (es) * 2009-05-20 2011-12-12 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c.
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CA2823066A1 (en) * 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) * 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20180030414A (ko) * 2015-07-30 2018-03-22 바이오마린 파머수티컬 인크. 골 이형성증 치료를 위한 c―형 나트륨이뇨 펩타이드 변이체의 용도

Also Published As

Publication number Publication date
IL278488B (en) 2022-10-01
EP3328416A1 (en) 2018-06-06
US11911446B2 (en) 2024-02-27
IL278488A (es) 2020-12-31
US20230293637A1 (en) 2023-09-21
BR112018001761A2 (pt) 2018-09-18
MX2023002973A (es) 2023-04-05
TWI773649B (zh) 2022-08-11
IL278488B2 (en) 2023-02-01
TWI820795B (zh) 2023-11-01
US20200246434A1 (en) 2020-08-06
JP2023144124A (ja) 2023-10-06
US11590204B2 (en) 2023-02-28
RU2728567C2 (ru) 2020-07-30
CN108472336A (zh) 2018-08-31
RU2020123892A (ru) 2020-09-18
RU2018106890A (ru) 2019-08-28
HK1255864A1 (zh) 2019-08-30
DK3328416T3 (da) 2024-04-08
AU2016298425B2 (en) 2022-11-10
US9907834B2 (en) 2018-03-06
CO2018002328A2 (es) 2018-05-10
CN114796460A (zh) 2022-07-29
CA2994280A1 (en) 2017-02-02
AU2016298425A1 (en) 2018-02-08
CA2994280C (en) 2024-01-23
JP2018522022A (ja) 2018-08-09
TW201717995A (zh) 2017-06-01
JP6882256B2 (ja) 2021-06-02
WO2017020034A8 (en) 2018-03-15
TW202322847A (zh) 2023-06-16
AU2023200669A1 (en) 2023-04-27
KR20180030414A (ko) 2018-03-22
US20180207239A1 (en) 2018-07-26
FI3328416T3 (fi) 2024-03-26
IL257125B (en) 2020-11-30
CN108472336B (zh) 2022-05-31
US20170028023A1 (en) 2017-02-02
US10646550B2 (en) 2020-05-12
IL257125A (en) 2018-03-29
CL2018000215A1 (es) 2018-06-22
RU2018106890A3 (es) 2019-12-27
JP2021107458A (ja) 2021-07-29
RU2020123892A3 (es) 2021-12-03
JP7336482B2 (ja) 2023-08-31
US20200246433A1 (en) 2020-08-06
EP3328416B1 (en) 2024-03-13
WO2017020034A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
MX2023002973A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
EP4019038A3 (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
EP3638298A4 (en) PEPTIDIC IMMUNOGENS FROM THE C-TERMINAL END OF A PROTEIN, ALPHA-SYNUCLEIN, AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF SYNUCLEINOPATHIES
MX2019000047A (es) Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2021013341A (es) Formas solidas de un inhibidor de glyt1.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
AU2018275270A1 (en) Peptide PAC1 antagonists
WO2015114633A8 (en) Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
WO2019055236A8 (en) Cyclin-dependent kinase 5 (cdk5) inhibitory peptides
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα
MX2018003289A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO.
AR105563A1 (es) Uso de variantes del péptido natriurético tipo c para tratar displasia esquelética